Contrasting Arcturus Therapeutics (ARCT) and Its Competitors

Arcturus Therapeutics (NASDAQ:ARCT) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Arcturus Therapeutics to related companies based on the strength of its analyst recommendations, risk, earnings, valuation, profitability, institutional ownership and dividends.

Volatility & Risk

Arcturus Therapeutics has a beta of 2.62, suggesting that its share price is 162% more volatile than the S&P 500. Comparatively, Arcturus Therapeutics’ rivals have a beta of 1.15, suggesting that their average share price is 15% more volatile than the S&P 500.

Institutional and Insider Ownership

94.5% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 17.8% of Arcturus Therapeutics shares are owned by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Arcturus Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Arcturus Therapeutics	$82.03 million	-$65.78 million	-3.36
Arcturus Therapeutics Competitors	$716.53 million	$12.10 million	-15.00

Arcturus Therapeutics’ rivals have higher revenue and earnings than Arcturus Therapeutics. Arcturus Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Arcturus Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Arcturus Therapeutics	-285.92%	-45.35%	-35.33%
Arcturus Therapeutics Competitors	-12,357.18%	-197.96%	-30.56%

Analyst Ratings

This is a breakdown of current ratings and price targets for Arcturus Therapeutics and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcturus Therapeutics	1	1	6	2	2.90
Arcturus Therapeutics Competitors	9834	15121	45433	1587	2.54

Arcturus Therapeutics presently has a consensus price target of $22.29, suggesting a potential upside of 115.32%. As a group, “Biotechnology” companies have a potential upside of 102.61%. Given Arcturus Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Arcturus Therapeutics is more favorable than its rivals.

Summary

Arcturus Therapeutics beats its rivals on 9 of the 13 factors compared.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.